| Cost‐Effectiveness analysis of biopharmaceuticals for treating rheumatoid arthritis: infliximab, adalimumab, and etanercept A Gholami, J Azizpoor, E Aflaki, M Rezaee, K Keshavarz BioMed Research International 2021 (1), 4450162, 2021 | 19 | 2021 |
| Cost of illness of COVID-19 and its consequences on health and economic system M Rajabi, M Rezaee, H Omranikhoo, A Khosravi, S Keshmiri, H Ghaedi, ... INQUIRY: The Journal of Health Care Organization, Provision, and Financing …, 2022 | 12 | 2022 |
| Economic burden of major depressive disorder: a case study in Southern Iran K Keshavarz, A Hedayati, M Rezaei, Z Goudarzi, E Moghimi, M Rezaee, ... BMC psychiatry 22 (1), 577, 2022 | 12 | 2022 |
| Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran M Rezaee, S Izadi, K Keshavarz, A Borhanihaghighi, R Ravangard Journal of medical economics 22 (4), 297-305, 2019 | 12 | 2019 |
| Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis M Rezaee, MH Morowvat, M Poursadeghfard, A Radgoudarzi, ... BMC health services research 22 (1), 118, 2022 | 10 | 2022 |
| Cost-effectiveness and cost-utility of CinnoVex versus ReciGen in patients with relapsing-remitting multiple sclerosis in Iran R Ravangard, M Rezaee, K Keshavarz, A Borhanihaghighi, S Izadi Shiraz E-Medical Journal 19 (11), 2018 | 5 | 2018 |
| Cost-effectiveness analysis of hearing screening program for primary school children in southern Iran, Shiraz M Faramarzi, S Babakhani Fard, M Bayati, F Jafarlou, M Parhizgar, ... BMC pediatrics 22 (1), 318, 2022 | 3 | 2022 |
| Outsourced Services and the Applied Models in Bushehr University of Medical Sciences in 2019 M Rezaee, H Salari, AH Darabi, H Omranikhoo, N Fardroo Iranian South Medical Journal 24 (1), 63-74, 2021 | 3 | 2021 |
| Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective F Lotfi, F Khodabandeh, A Jafari, M Rezaee, H Rahimi, Z Shiravani, ... Expert Review of Pharmacoeconomics & Outcomes Research 23 (4), 439-447, 2023 | 2 | 2023 |
| Economic burden of multiple sclerosis: a cross-sectional study in Iran M Rezaee, K Keshavarz, S Izadi, A Jafari, R Ravangard Health Economics Review 12, 1-10, 2022 | 2 | 2022 |
| Exposure of Public Sector with the Quasi-market Through Outsourcing: A Case Study in Iran HS Habib Omranikhoo , Sanaz Zargar Balaye Jame, Farhad Lotfi, Mehdi Rezaee ... Thrita 11 (2), e105930, 2022 | 2 | 2022 |
| Investigating the Inequality Trend in Health Resource Distribution in Iran: A Case Study in Bushehr Province M Rezaee, M Azmal, F Lotfi, H Omranikhoo Shiraz E-Medical Journal, 2024 | | 2024 |
| Cost-effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients with Metastatic Prostate Cancer: A Societal Perspective M Rezaee, I Karimzadeh, A Hashemi-Meshkini, S Zeighami, M Bazyar, ... Value in Health Regional Issues 42, 100982, 2024 | | 2024 |
| Financial Indicators of Public Autonomous Hospitals: A Case Study in Bushehr Province in 2021 M Rezaee, M Shahbazifard, H Omranikhoo Iranian South Medical Journal 26 (2), 114-126, 2023 | | 2023 |
khosro keshavarzAssociate Professor of Pharmacoeconomics at Shiraz University of Medical SciencesVerified email at sums.ac.ir
